Review article: Biosimilars are the next generation of drugs for liver and gastrointestinal diseases

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 8, 2013, Pages 914-924

  Rinaudo Gaujous, M ^a   Paul, S ^a   Tedesco, E D ^a   Genin, C ^a   Roblin, X ^a   Peyrin Biroulet, L ^b  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTINEOPLASTIC AGENT; AVENT; B 1695501; BIOSIMILAR AGENT; CT P 13; EP 2006; ETANERCEPT; FOLIC ACID; GLYCERYL TRINITRATE; GP 2013; HD 203; HEMOGLOBIN; HEXAL; HUMAN GROWTH HORMONE; INFLIXIMAB; INTERFERON; LBEC 0101; METHOTREXATE; NEUTRALIZING ANTIBODY; PEGINTERFERON; PF 06410293; PLD 108; PR X 106; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; RITUXIMAB; SB 309; SILAPRO; TUNEX; UNCLASSIFIED DRUG; XM 02;

AGRANULOCYTOSIS; AMINO ACID SEQUENCE; ANKYLOSING SPONDYLITIS; AREA UNDER THE CURVE; AUTOIMMUNE DISEASE; BINDING AFFINITY; BIOEQUIVALENCE; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE EFFECTIVENESS; COST CONTROL; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDICATION; DRUG MANUFACTURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ENGRAFTMENT; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GLYCOSYLATION; HEPATITIS C; HUMAN; IMMUNOGENICITY; LIVER DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PHARMACEUTICAL EQUIVALENCE; PRIORITY JOURNAL; REGISTRATION; REVIEW; RHEUMATOID ARTHRITIS; STEM CELL MOBILIZATION; STUDY DESIGN; THERAPEUTIC EQUIVALENCE; UNSPECIFIED SIDE EFFECT;

ANIMALS; BIOSIMILAR PHARMACEUTICALS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; GASTROINTESTINAL DISEASES; HUMANS; LIVER DISEASES;

EID: 84884910025     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12477     Document Type: Review

References (58)

1. Krämer I,. Pharmacy and pharmacology of biosimilars. J Endocrinol Invest 2008; 31: 479-88.
2. Schneider CK, Kalinke U,. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26: 985-90.
3. McCamish M, Woollett G,. The rise of the biosimilar. Expert Rev Clin Pharmacol 2012; 5: 597-9.
4. Malik NN,. Controlling the cost of innovative cancer therapeutics. Nat Rev Clin Oncol 2009; 6: 550-2.
5. 2010 report generic savings GPhA. Available at: http://www. prescriptionaccess.org/2010-Report-Generic-Savings-GPhA.pdf. Accessed July 10, 2013.
6. Congressional budget office cost estimate. Available at: http://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/94xx/doc9496/s1695.pdf. Accessed July 10, 2013.
7. Jelkmann W,. Biosimilar epoetins and other 'follow-on' biologics: update on the European experiences. Am J Hematol 2010; 85: 771-80.
8. Mellstedt H, Niederwieser D, Ludwig H,. The challenge of biosimilars. Ann Oncol Off J Eur Soc Med Oncol Esmo 2008; 19: 411-9.
9. Weise M, Bielsky M-C, De Smet K, et al,. Biosimilars: what clinicians should know. Blood 2012; 120: 5111-7.
10. Quality considerations in demonstrating biosimilarity to a reference protein product. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf. Accessed July 11, 2013.
11. Schellekens H,. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 1: 457-62.
12. Schellekens H, Ryff J-C,. 'Biogenerics': the off-patent biotech products. Trends Pharmacol Sci 2002; 23: 119-21.
13. Zelenetz AD, Ahmed I, Braud EL, et al,. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Cancer Netw Jnccn 2011; 9 (Suppl. 4): S1-22.
14. Kuhlmann M, Covic A,. The protein science of biosimilars. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc-Eur Ren Assoc 2006; 21 (Suppl. 5): v4-8.
15. Crommelin D, Bermejo T, Bissig M, et al,. Biosimilars, generic versions of the first generation of therapeutic proteins: do they exist? Contrib Nephrol 2005; 149: 287-94.
16. Crommelin DJA, Storm G, Verrijk R, et al,. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm 2003; 266: 3-16.
17. Schiestl M, Stangler T, Torella C, et al,. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29: 310-2.
18. McCamish M, Woollett G,. The state of the art in the development of biosimilars. Clin Pharmacol Ther 2012; 91: 405-17.
19. GPhAcomments. Available at: http://www.elsevierbi.com/∼/media/ Supporting%20Documents/The%20Pink%20Sheet/74/17/GPhAcomments.pdf. Accessed July 12, 2013.
20. Chow S-C, Wang J, Endrenyi L, et al,. Scientific considerations for assessing biosimilar products. Stat Med 2013; 32: 370-81.
21. Guideline on similar biological medicinal products. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003517.pdf. Accessed July 11, 2013.
22. EMA procedural advice for users of the centralised procedure for generic/hybrid applications. Available at: http://www.ema.europa.eu/docs/en-GB/ document-library/Regulatory-and-procedural-guideline/2009/10/WC500004018.pdf. Accessed July 11, 2013.
23. CHAPTER 1 marketing authorisation rev, 2005. Available at: http://ec.europa.eu/health/files/eudralex/vol-2/a/vol2a-chap1-2005-11-en.pdf. Accessed July 11, 2013.
24. Test procedures and acceptance criteria for biotechnological/biological products. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500002824.pdf. Accessed July 11, 2013.
25. Step 5 preclinical safety evaluation of biotechnology-derived pharmaceuticals. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500002828.pdf. Accessed July 11, 2013.
26. Quality of biotechnological products: stability testing of biotechnological/biological products. Available at: http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002803.pdf. Accessed July 11, 2013.
27. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003920.pdf. Accessed July 11, 2013.
28. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/ 2009/09/WC500003953.pdf. Accessed July 11, 2013.
29. Niederwieser D, Schmitz S,. Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol 2011; 86: 277-88.
30. Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues. Available at: http://www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/06/WC500128686. pdf. Accessed July 11, 2013.
31. Scientific considerations in demonstrating biosimilarity to a reference product. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed July 11, 2013.
32. WHO expert committee on biological standardization. Available at: http://www.who.int/biologicals/areas/biological-therapeutics/ BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf. Accessed July 11, 2013.
33. Dranitsaris G, Dorward K, Hatzimichael E, et al,. Clinical trial design in biosimilar drug development. Invest New Drugs 2013; 31: 479-87.
34. Schumi J, Wittes JT,. Through the looking glass: understanding non-inferiority. Trials 2011; 12: 106.
35. Rothmann M, Li N, Chen G, et al,. Design and analysis of non-inferiority mortality trials in oncology. Stat Med 2003; 22: 239-64.
36. Ware JH, Antman EM,. Equivalence trials. N Engl J Med 1997; 337: 1159-61.
37. Blackwelder WC,. 'Proving the null hypothesis' in clinical trials. Control Clin Trials 1982; 3: 345-53.
38. Brinks V, Hawe A, Basmeleh AHH, et al,. Quality of original and biosimilar epoetin products. Pharm Res 2011; 28: 386-93.
39. Sörgel F, Thyroff-Friesinger U, Vetter A, et al,. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial. BMC Clin Pharmacol 2009; 9: 10.
40. Haag-Weber M, Vetter A, Thyroff-Friesinger U, et al,. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 2009; 72: 380-90.
41. Hörl WH, Locatelli F, Haag-Weber M, et al,. Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10-12 g/dl. Clin Nephrol 2012; 78: 24-32.
42. Mikhail A, Farouk M,. Epoetin biosimilars in Europe: five years on. Adv Ther 2013; 30: 28-40.
43. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, et al,. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011; 80: 88-92.
44. European Medicines Agency. Assessment report for ratiograstim. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/000825/WC500047793.pdf. Accessed July 15, 2013.
45. Schmitt M, Xu X, Hilgendorf I, et al,. Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors. Bone Marrow Transplant 2013; 48: 922-5.
46. Publicover A, Richardson DS, Davies A, et al,. Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. Br J Haematol 2013; 162: 107-11.
47. Visser J, Feuerstein I, Stangler T, et al,. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. Biodrugs Clin Immunother Biopharm Gene Ther 2013 (in press). PMID: 23649935.
48. Vigani AG, Gonçales ES, Pavan MHP, et al,. Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3. Braz J Infect Dis Off Publ Braz Soc Infect Dis 2012; 16: 232-6.
49. Therapy: biosimilar CT-P13 comparable to infliximab in active RA. Nat Rev Rheumatol 2013; 9: 382.
50. Appendix A PLANETAS study Ann Rheum Dis, 2013. Available at: http://ard.bmj.com.gate2.inist.fr/content/suppl/2013/05/16/annrheumdis-2012- 203091.DC1/annrheumdis-2012-203091supp-appendixA.pdf. Accessed July 11, 2013.
51. Park W, Hrycaj P, Jeka S, et al,. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013 (in press). PMID: 23687259.
52. Yoo DH, Hrycaj P, Miranda P, et al,. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013 (in press). PMID: 23687260.
53. Danese S, Gomollon F,; Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013; 7: 586-589.
54. Gecse KB, Khanna R, van den Brink GR, et al,. Biosimilars in IBD: hope or expectation? Gut 2013; 62: 803-7.
55. EMA inflectra initial MAA-summary of opinion. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial- authorisation/human/002778/WC500144831.pdf. Accessed July 11, 2013.
56. Gu N, Yi S, Kim T-E, et al,. Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers. Clin Ther 2011; 33: 2029-37.
57. ®): a double-blind, single-dose, crossover study in healthy volunteers. Biodrugs Clin Immunother Biopharm Gene Ther 2012; 26: 177-84.
58. Beck A,. Biosimilar, biobetter and next generation therapeutic antibodies. MAbs 2011; 3: 107-10.